Stockreport

Sagimet Biosciences Provides Strategic and Corporate Updates [Yahoo! Finance]

Sagimet Biosciences Inc.  (SGMT) 
PDF First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH development to be undertaken only upon securing non-dilutive funding Sagimet t [Read more]